目的:运用文献计量方法分析microRNA-375在肝细胞癌中的研究现状、热点及发展趋势,为该领域未来研究提供数据参考。方法:基于Web of Science核心合集中2013~2022年有关microRNA-375在肝细胞癌中的相关研究数据,利用可视化分析软件CiteSp...目的:运用文献计量方法分析microRNA-375在肝细胞癌中的研究现状、热点及发展趋势,为该领域未来研究提供数据参考。方法:基于Web of Science核心合集中2013~2022年有关microRNA-375在肝细胞癌中的相关研究数据,利用可视化分析软件CiteSpace和VOSviewer对文献年度发表量、国家、研究机构、来源期刊、活跃作者及关键词进行文献计量和可视化分析。结果:截至2023年9月15日,共有46,808篇microRNA-375与肝细胞癌的相关研究发表。文献发表量呈逐年上升趋势,中国是最高产的国家,其次是美国和日本,法国中心性最高。Oncotarget发文量最高,Hepatology被引用频次最高。高发文量机构主要集中在中国,Sun Yat-sen University发文量最多,University of California System中心性位列第一。此外,“open label”、“tumor microenvironment”、“phase iii”、“immune checkpoint inhibitors”、“immune infiltration”、“microenvironment”等是该领域的研究热点。结论:本研究通过文献计量分析方法对microRNA-375与肝细胞癌进行了全面概述,为关注该领域的科研人员提供线索。展开更多
Background： MicroRNAs （miRNAs） are key regulators during tumor initiation and progression. MicroRNA-375 （MiR-375） has been proven to play a tumor-suppressive role in various types of human malignancies; however, ...Background： MicroRNAs （miRNAs） are key regulators during tumor initiation and progression. MicroRNA-375 （MiR-375） has been proven to play a tumor-suppressive role in various types of human malignancies; however, its biological role in clear cell renal cell carcinoma （ccRCC） remains unclear. The purpose of this study was to explore the biologic role as well as the underlying mechanism of miR-375 in ccRCC progression. Methods： Quantitative polymerase chain reaction （qPCR） was applied to test the expression of miR-375 in tissues and cell lines by t-test. Functional experiments were used to investigate the biological role of miR-375 utilizing a gain-of-function strategy. The target of miR-375 was investigated by bioinformatic analysis and further verified by luciferase reporter assay, qPCR, Western blotting, and functional experiments in vitro. Results： Our study demonstrated that miR-375 was significantly downregulated in ccRCC tissues （cancer vs. normal, 0.804 ±0.079 vs. 1.784 ± 0.200, t = 5.531 P 〈 0.0001 ） and cell lines, and loss ofmiR-375 expression significantly associated with advanced Fuhrman nuclear grades （Grade Ⅲ and Ⅳ vs. Grade Ⅰ and Ⅱ, 1.000 ± 0.099 vs. 1.731 ± 0.189, t = 3.262 P = 0.003）. Functional studies demonstrated that miR-375 suppressed ccRCC cell proliferation, migration, and invasion （all P 〈 0.05 in both 786-0 and A498 cell lines）. Multiple miRNA target prediction algorithms indicated the well-studied oncogene YWHAZ as a direct target ofmiR-375, which was further confirmed by the luciferase reporter assay, qPCR, and Western blotting. Moreover, restoration of YWHAZ could rescue the antiproliferation effect ofmi R-375. Conclusions： The data provide the solid evidence that miR-375 plays a tumor-suppressive role in ccRCC progression, partially through regulating YWHAZ. This study expands the antitumor profile ofmiR-375, and supports its role as a potential therapeutic target in ccRCC treatment.展开更多
文摘目的:运用文献计量方法分析microRNA-375在肝细胞癌中的研究现状、热点及发展趋势,为该领域未来研究提供数据参考。方法:基于Web of Science核心合集中2013~2022年有关microRNA-375在肝细胞癌中的相关研究数据,利用可视化分析软件CiteSpace和VOSviewer对文献年度发表量、国家、研究机构、来源期刊、活跃作者及关键词进行文献计量和可视化分析。结果:截至2023年9月15日,共有46,808篇microRNA-375与肝细胞癌的相关研究发表。文献发表量呈逐年上升趋势,中国是最高产的国家,其次是美国和日本,法国中心性最高。Oncotarget发文量最高,Hepatology被引用频次最高。高发文量机构主要集中在中国,Sun Yat-sen University发文量最多,University of California System中心性位列第一。此外,“open label”、“tumor microenvironment”、“phase iii”、“immune checkpoint inhibitors”、“immune infiltration”、“microenvironment”等是该领域的研究热点。结论:本研究通过文献计量分析方法对microRNA-375与肝细胞癌进行了全面概述,为关注该领域的科研人员提供线索。
基金This work was supported by the grants from the National Natural Science Foundation of China （No. 81702521） and Provincial Natural Science Foundation of Shandong （No. ZR2017PH019 and No. ZR2018BH018）.
文摘Background： MicroRNAs （miRNAs） are key regulators during tumor initiation and progression. MicroRNA-375 （MiR-375） has been proven to play a tumor-suppressive role in various types of human malignancies; however, its biological role in clear cell renal cell carcinoma （ccRCC） remains unclear. The purpose of this study was to explore the biologic role as well as the underlying mechanism of miR-375 in ccRCC progression. Methods： Quantitative polymerase chain reaction （qPCR） was applied to test the expression of miR-375 in tissues and cell lines by t-test. Functional experiments were used to investigate the biological role of miR-375 utilizing a gain-of-function strategy. The target of miR-375 was investigated by bioinformatic analysis and further verified by luciferase reporter assay, qPCR, Western blotting, and functional experiments in vitro. Results： Our study demonstrated that miR-375 was significantly downregulated in ccRCC tissues （cancer vs. normal, 0.804 ±0.079 vs. 1.784 ± 0.200, t = 5.531 P 〈 0.0001 ） and cell lines, and loss ofmiR-375 expression significantly associated with advanced Fuhrman nuclear grades （Grade Ⅲ and Ⅳ vs. Grade Ⅰ and Ⅱ, 1.000 ± 0.099 vs. 1.731 ± 0.189, t = 3.262 P = 0.003）. Functional studies demonstrated that miR-375 suppressed ccRCC cell proliferation, migration, and invasion （all P 〈 0.05 in both 786-0 and A498 cell lines）. Multiple miRNA target prediction algorithms indicated the well-studied oncogene YWHAZ as a direct target ofmiR-375, which was further confirmed by the luciferase reporter assay, qPCR, and Western blotting. Moreover, restoration of YWHAZ could rescue the antiproliferation effect ofmi R-375. Conclusions： The data provide the solid evidence that miR-375 plays a tumor-suppressive role in ccRCC progression, partially through regulating YWHAZ. This study expands the antitumor profile ofmiR-375, and supports its role as a potential therapeutic target in ccRCC treatment.
